CLPP
protein-codingcaseinolytic mitochondrial matrix peptidase proteolytic subunit, the group of AAA ATPases
Gene summary
The protein encoded by this gene belongs to the peptidase family S14 and hydrolyzes proteins into small peptides in the presence of ATP and magnesium. The protein is transported into mitochondrial matrix and is associated with the inner mitochondrial membrane. [provided by RefSeq, Jul 2008]
MANE transcript
Inheritance
ClinVar variants
Top phenotype
gnomAD constraint
Max pathogenic AF
Genomic locus
External References & Databases
Transcript & Mutation Effects
hg38 • Region Span ~8.8 kbGenCC Phenotypes & Disease Associations
Curated gene-disease validity assertions and inheritance patterns
Inheritance Pattern: AR
Disease ID:MONDO:0013588
Submitter: ClinGen
The CLPP gene has been associated with autosomal recessive Perrault syndrome using the ClinGen Clinical Validity Framework as of 11/6/2017. This association was made using case-level data only. At least 11 missense, splice site and frameshift variants have been reported in humans. CLPP was first associated with this disease in humans as early as 2007 (Ain et al.). Association is seen in at least 11 probands in 7 publications (23541340, 27087618, 26970254, 27650058, 25956234, 27899912, 28604674). Variants in this gene segregated with disease in 13 additional family members. This gene-disease association is supported by expression studies and a null mouse model with hearing loss and infertility. In summary, CLPP is definitively associated with autosomal recessive Perrault syndrome. This classification was approved by the ClinGen Hearing Loss Working Group on 3/27/2018.
Inheritance Pattern: AR
Disease ID:MONDO:0013588
Submitter: G2P
Inheritance Pattern: AR
Disease ID:MONDO:0013588
Submitter: Labcorp Genetics (formerly Invitae)
Clinical Genomic Database (CGD)
Manifestation: Audiologic/Otolaryngologic; Endocrine; Neurologic; Obstetric
Intervention: Audiologic/Otolaryngologic; Obstetric
Rationale: Early recognition and treatment of hearing impairment may improve outcomes, including speech and language development; Genetic knowledge may allow fertility preservation such as by storing eggs
ClinVar Associated Diseases & Phenotypes
Reported disease conditions connected to CLPP variants in ClinVar
ClinVar Variants & Pathogenicity by Type
Statistics based on transcript NM_006012.4. Only rare variants are included.
We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.
Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 2 | 58 | 2 | 62 | ||
| missense | 3 | 8 | 75 | 3 | 89 | |
| nonsense | 1 | 1 | ||||
| start loss | 1 | 1 | 2 | |||
| frameshift | 6 | 1 | 7 | |||
| splice donor/acceptor (+/-2bp) | 1 | 4 | 2 | 7 | ||
| Total | 11 | 14 | 80 | 61 | 2 | 168 |
Highest pathogenic variant AF is 0.00000982007
Transcript Catalog
Annotated transcript isoforms across RefSeq and Ensembl databases
| Transcript ID | Source | Protein ID | Coding Exons | MANE Status |
|---|---|---|---|---|
| RefSeq | NP_006003.1 | 6 | MANE Select | |
| Ensembl | ENSP00000245816.3 | 6 | MANE Select | |
| Ensembl | ENSP00000472227.1 | 5 | Standard | |
| Ensembl | ENSP00000472227.1 | 5 | Standard |
Gene Ontology (GO) Annotations & Pathways
Biological processes, molecular functions, cellular components and pathways
Biological Process
- protein quality control for misfolded or incompletely synthesized proteins
- protein homooligomerization
- proteolysis involved in cellular protein catabolic process
Molecular Function
- ATP-dependent peptidase activity
- serine-type endopeptidase activity
- protein binding
- peptidase activity
- identical protein binding
Cellular Component
- mitochondrion
- mitochondrial matrix
- endopeptidase Clp complex
gnomAD Constraint
Source:
- Gene type
- protein_coding
- Transcript type
- protein_coding
- Transcript
- ENST00000245816
- Coding exons
- 6
- Length
- 7457
- Individuals with no LoFs
- 125377
- Homozygous LoFs
- 0
- Heterozygous LoFs
- 3
- Defined
- 125380
- p
- 0.0000120
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible | |
|---|---|---|---|---|---|---|
| Missense | 1.95 | 93 | 163 | 0.570 | 0.00000934 | 1750 |
| Missense (PolyPhen) | 22 | 67.928 | 0.32387 | 709 | ||
| Synonymous | -0.517 | 75 | 69.5 | 1.08 | 0.00000451 | 564 |
| Loss of Function | 2.54 | 2 | 11.1 | 0.179 | 4.77e-7 | 125 |
Population LoF Frequency
| Population | CAF | p-value | Status |
|---|---|---|---|
| African | 0 | 0.0 | absent |
| Latino/Admixed American | 0.000030 | 0.000029 | rare |
| Ashkenazi Jewish | 0 | 0.0 | absent |
| East Asian | 0 | 0.0 | absent |
| Finnish | 0 | 0.0 | absent |
| European (Non-Finnish) | 0.0000092 | 0.0000088 | rare |
| South Asian | 0.000033 | 0.000033 | rare |
| Other | 0 | 0.0 | absent |
dbNSFP Gene Annotations
Source:
- Function
- FUNCTION: Protease component of the Clp complex that cleaves peptides and various proteins in an ATP-dependent process. Has low peptidase activity in the absence of CLPX. The Clp complex can degrade CSN1S1, CSN2 and CSN3, as well as synthetic peptides (in vitro) and may be responsible for a fairly general and central housekeeping function rather than for the degradation of specific substrates. {ECO:0000269|PubMed:11923310, ECO:0000269|PubMed:15522782}.;
Recessive Scores
- pRec
- 0.362
Intolerance Scores
- LoFtool
- 0.216
- RVIS EVS
- -0.34
- RVIS percentile EVS
- 30.07
Essentials
- Essential (CRISPR)
- N
- Essential (CRISPR2)
- S
- Essential (gene trap)
- N
- Indispensability pred.
- E
- Indispensability score
- 0.922
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Low | Low |
| Primary Immunodeficiency | Medium | Low | Medium |
| Cancer | Medium | Medium | Medium |